Mark A. Reddish

Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers

Shelly McNeil, Scott A. Halperin, Joanne M. Langley et al. · Clinical Infectious Diseases · 2005 · 305 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

Babita Agrawal, Mark J. Krantz, Mark A. Reddish et al. · Nature Medicine · 1998 · 300 citations

Medicine, Cancer Biology, Oncology +10

The Selectivity and Functional Connectivity of the Anterior Temporal Lobes

W. Kyle Simmons, Mark A. Reddish, Patrick S.F. Bellgowan et al. · Cerebral Cortex · 2009 · 249 citations · Full text

Social Sciences, Neuroscience, Psychology +16

Immunogenicity of a 26-Valent Group A Streptococcal Vaccine

Mary C. Hu, Michael A. Walls, Steven D. Stroop et al. · Infection and Immunity · 2002 · 242 citations · Full text

Life Sciences, Immunology, Immunization +16

Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn Vaccine

Grant D. MacLean, Mark A. Reddish, R. Rao Koganty et al. · Journal of Immunotherapy · 1996 · 183 citations

Life Sciences, Immunology, Oncology +17